MONTRÉAL, QC, Nov. 6, 2012 /CNW/ -
Aptilon Corporation ("Aptilon" or the "Corporation")
(TSX-V: APZ) today announced that its wholly-owned subsidiary,
Aptilon Holdings Inc. ("Holdings"), has come to an agreement with
regards to the sale of substantially all of its assets related to
its business of providing multichannel, e-detailing and physician
marketing services to members of the healthcare industry (the
"Business") to Indegene Aptilon, Inc. ("Indegene Aptilon"). The
sale of these assets will allow Aptilon to focus its activities on
the healthcare marketing and data services business it acquired in
September 2009.
Indegene Aptilon is a wholly-owned subsidiary of
Indegene Lifesystems Pvt, Ltd., and it deals at arm's length with
Aptilon and Holdings.
The sale of the Business is made for a price of
$1,500,000 payable in cash at the
closing plus earnout amounts based on the EBITDA of the Business
for the quarter ending December 31,
2012 and the year ending December 31, 2013. The maximum earnout
amount for the quarter ending December 31, 2012 is $500,000 payable on June 30, 2013. The earnout amount for the
year ending December 31, 2013 is
$2,000,000 if the EBITDA target is
fully met (such earnout amount may be increased if the EBITDA
target is exceeded) payable on June 30,
2014.
The closing of the sale will occur as soon as
possible, and is subject to various conditions including the
obtaining of the necessary approvals from the regulatory
authorities, Indegene Aptilon's satisfaction with its due diligence
and the consents of third parties to the assignment of material
contracts. Although Aptilon's management is not currently aware of
any impediments, there are no assurances that the closing
conditions will be met.
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device
companies to effectively reach, message, connect and interact with
US physicians and healthcare professionals via multiple access
channels. Its innovative service offerings provide targeted
impressions and interactions through: video and mobile detailing,
digital access channels and permission-based email services. Top
pharmaceutical companies and respected healthcare organizations
have adopted Aptilon's solutions to market to, engage and interact
with leading healthcare practitioners. For more information, visit
www.aptilon.com.
About Indegene
Indegene is a leading provider of R&D, commercial and marketing
solutions to global pharmaceutical and healthcare organizations. We
partner with clients to drive both productivity and revenues by
delivering better patient outcomes, optimizing cost, enhancing
R&D agility, and improving sales and marketing effectiveness.
We apply deep scientific knowledge, flexible delivery models,
proprietary technology, and a client-centric approach to drive
transformational initiatives.
With offices in US, UK, China, India,
and Australia, Indegene can
partner globally with clients, leverage a global talent pool of
clinicians, technologists, creative specialists, domain experts,
business process specialists, deploy global infrastructure assets,
and harness global healthcare knowledge to solve client challenges.
For more information, visit www.indegene.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE Aptilon Corporation